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Objective: To assess the quality of life, investigate complications and adverse transfusion reactions post blood transfusion in thalassemia pediatric. 
ABSTRACT 
Methods: A prospective, observational study was conducted over a period of six months in the pediatric department of Bharati hospital and 
research center, Pune. Thalassemia patient profile form was used for collecting demographic details, to record adverse transfusion reactions and 
complications. Using PedsQL™ (Pediatric Quality of Life Inventory) questionnaire thalassemia patients, and the control group was interviewed to 
assess their quality of life. 
Results: Out of 39 patients who were enrolled, 28 patients were above the age of 3 y; their overall quality of life score was significantly lower in 
thalassemia pediatric than healthy control. School function was a most affected domain. 53.84% had post-transfusion fever, 5.1% of respiratory 
distress while 41.06% had myalgia, swelling at IV site, headache, and vomiting. Out of 39 patients, 24 patients examined for complications; 33.34% 
had hepatosplenomegaly, 25% had infections, 16.66% had splenomegaly, 13.88% had cardiac complications, 8.34% had bone deformity, and 2.78% 
had growth failure. 
Conclusion: It was found that there was a significant decrease in the quality of life domains in thalassemia pediatric compared to control group. 
School domain was most affected. Hepatosplenomegaly is one of the leading complications observed in this study. Most common transfusion-related 
reaction was post-transfusion fever. Public awareness and preventive measures such as pre-marital and prenatal testing should be done to 
eliminate this fatal disease. 
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INTRODUCTION 
Thalassemia is one of the major hemoglobinopathies among the 
population all around the world. It is a single-gene hereditary disorder 
in a human. It is caused due to decreased or absent amount of globin 
chain of hemoglobin [1]. It occurs when there is an abnormality or 
mutation in one of the genes involved in hemoglobin production, 
which is inherited from both parents [2]. The average incidence of ß-
thalassemia trait in India is 3.3% with 1–2 per 1,000 couples being at 
risk of having an affected offspring each year. The incidence of β-
thalassemia in different regions of India varies from 3% to 17%, with a 
mean prevalence of 4% [3]. It is very high among certain communities 
such as Sindhis and Punjabis from Northern India, Bhanushalis, 
Kutchis, Lohanas from Gujarat, Mahars, Neobuddhists, Kolis and Agris 
from Maharashtra, Gowdas and Lingayats from Karnataka etc. and 
certain tribes in the northern, western and eastern parts, with lower 
incidence in the southern tribes [4]. Patients with beta thalassemia 
major usually become symptomatic by about 4–6 mo of age and 
without transfusion support, progressive anemia causes decreased 
growth and development, heart failure, and eventually premature 
death. Without transfusions, very few patients survive beyond 5 y of 
age [5]. The management of thalassemia includes regular blood 
transfusion, iron chelation therapy, and appropriate management of 
co-morbidities [6]. The more thalassemia major develops into a 
chronic disease with an expanding life expectancy, the more patient 
quality of life is becoming an important dimension of care. It is a 
potential life-threatening condition causing a substantial disturbance 
in education and social activities [7]. Based on literature survey, it was 
observed that few studies were conducted on the effect of thalassemia 
on the quality of life in patients and also fewer studies were available 
to address, document adverse transfusion reactions and complications 
associated with thalassemia in India. The positive impact of treatment 
diminishes, especially in terms of health-related quality of life if they 
interfere with daily activities or are less tolerable e. g. regular blood 
transfusion that requires frequent hospital visits. As children are less 
able to voice their concern and are more vulnerable than adults, the 
assessment of health-related quality of life in children is essential for 
the provision of proper care, since it helps in identifying the impact of 
disease and treatment from the children’s perspective. Even if in 
recent years the innovative research strategies for thalassemia major 
have greatly increased life expectancy which varies between 25-55 y, 
the fear of the disease itself and possible complications of invasive 
medical procedures, still affect the quality of life of patients. Also, it is 
important to assess long-term disease complication and adverse 
transfusion reactions due to blood transfusions, which will further 
help in improving the quality of life. 
Therefore, the objective of the present study is to assess the quality 
of life in beta thalassemia pediatric using PedsQL™ version 4.0 
(Pediatric Quality of Life Inventory) questionnaires, to identify and 
assess the types of complications and adverse transfusion reactions.  
MATERIALS AND METHODS 
The study was carried out for 6 mo duration at Bharati Medical 
Hospital, and Research Centre, Dhankawadi, Pune and an 
Institutional Ethical Committee clearance was obtained with an 
ethics vide letter no. BVDU/MC/76. The study was conducted among 
children and adolescent with beta thalassemia major who received 
blood transfusion regularly at Bharati hospital. A random sample of 
healthy school going children of age 2-18 y was selected as the 
control group for comparing the quality of life.  
An information sheet was explained to parents. Assent was taken 
from parents of both patients and control group who were enrolled 
in the study. Patient’s demographic data and clinical data were noted 
down in a specially designed thalassemia patient profile form. 
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Patients and their parents were interviewed about the patient’s 
quality of life and if they experience any adverse reactions post 
blood transfusions when they visit for subsequent blood transfusion. 
The interview was carried out by administering PedsQLTM 
Data was analyzed by Microsoft Excel 2007 result was calculated in 
terms of percentage, mean, standard deviation (SD) and was also 
used for graphical representation. The quality of life comparison 
between thalassemia pediatrics and control group was analyzed 
using one-way ANOVA for which p>0.05 shows a significant 
difference between thalassemia pediatrics and control group. 
version 
4.0 questionnaires for assessing their quality of life. The 
questionnaire had choices “never”, “almost never”, “sometimes”, 
“often’, and “almost always”, with corresponding scores of 100, 75, 
50, 25, and 0. Each patient was given a score from 0-100, with higher 
scores indicating better health or a higher level of function. At the 
end of the study, the questionnaire was analyzed, and adverse 
transfusion reactions were documented. The same procedure was 
followed to interview the children from the control about their 
quality of life. 
RESULTS 
In a study period of six months total number of patients who were 
screened for beta thalassemia major were 48 patients, out of which 
39 patients were enrolled for the study based on inclusion criteria, 2 
patients were excluded as they did not meet the inclusion criteria, 
while 7 patients left blood transfusion follow-up from Bharati 
Hospital, as it was not feasible for them to continue the blood 
transfusion follow-up in the hospital. 
Among 39 patients, 28 were male and 11 were female with the mean age 
of 6 y±4.32. 14 (35.90%) patients belonged to the age group of 1-3 y, 
followed by 9 (23.08%) each in age group of 4-6 y and 7-9 y respectively 
while 7 (17.94%) were in the age group of 10-18years. It was observed 
that 9 (23.07%) were in pre-primary, 10 (25.65%) in primary, 6 
(15.38%) in secondary, 11 (28.21%) were not attending school as they 
were under the age of 3 y, while 3 (7.69%) left school as they were not 
comfortable with the school environment. To evaluate the quality of life 
in patients with beta thalassemia major, a control group of 28 was 
introduced, who were in the age range of 1–18 y. Among them, 18 
(64.28%) were male and 10 (35.72%) were female. 14 (50%) were in 
the age group of 4-6 y. Children from the control group were randomly 
selected among school going, children. Most of them were from primary 
education level (46.43%) (table 1).  
From the data collected it was found that most of the patients had 
blood group B+ve 14 (35.90%), followed by O+ve 10 (25.65%), A+ve 
8 (20.52%), AB+ve 4 (10.25%), B-ve 2 (5.12%) and AB-ve 1 (2.56%) 
(table 2).  
In the present study, it was observed that 20 (51.28%) had a 
consanguineous marriage while 19 (48.72%) had non-
consanguineous marriage (fig. 1). 
It was observed that 23 patients (58.98%) were diagnosed among the 
age group of 3-6 mo, 6 (15.39%) among the age group of 7-9 mo, 5 
(12.82%) with age greater than 1 y, followed by patients with age group 
of 10-12 mo 4 (10.25%), 1 patient of age less than 3 mo (2.56%) (fig. 2).  
From the data collected it was observed that patients complained of 
pallor, fever, cough, coryza, weakness at the time of diagnosis. Other 
symptoms which were seen are chills, irritability, abdominal pain, 
vomiting, decreased oral intake, edema, breathlessness, diarrhea, 
headache, body ache, joint pain (table 3).  
It was found that about 21 patients (53.84%) had Hb between 
ranges of 2.0-4.9 g/dl followed by 15 patients (38.46%) had Hb 
between the range of 5.0-7.9 g/dl and 3 patients (7.70%) had Hb 
less than 8.0 g/dl at the age of diagnosis. (fig. 3).  
The data showed that 9 patients (23.10%) of thalassemia children 
had parents who were both carriers. In 1 patient (2.55%) only 1 of 
the parent was a carrier and in 29 (74.35%) parents were not 
screened for beta thalassemia (table 4).  
The data collected showed that among 39 patients, 15 (38.46%) had 
no siblings while 13 (33.34%) patients had siblings who were not 
affected while 5 patients (28.20%) had siblings who were affected 
with beta thalassemia (fig. 4).  
Comparison data showed that there was a significant difference of 
quality of life between thalassemia pediatrics and control group. 
Assessments of four quality of life domains in thalassemia pediatrics vs. 
control group showed the following: physical function 55.45 vs. 89.23 (p 
value= 0.9930), emotional function 62.32 vs. 92.85 (0.9752), social 
function 62.14 vs. 92.85 (p value= 0.9332) and school function 46.42 vs. 
85.53 (p value= 0.9992). One way ANOVA test was used to compare 
thalassemia pediatrics and control group and it was found to be p>0.05. 
This shows that there was a significant difference between thalassemia 
pediatrics and control group.  
In the present study, it was observed that overall the quality of life 
score was less in thalassemia pediatrics indicating that their quality 
of life was affected due to the disease and among all quality of life 
domains; school function was the most affected domain (fig. 5).  
From the data collected it was found that most common blood 
transfusion reactions were fever, respiratory distress while other 
blood transfusion reactions which didn’t occur commonly were 
headache, vomiting, swelling at injection site, tachypnea (table 5).  
It was observed that 20 patients (51.28 %) came for blood 
transfusion when their pre-transfusion Hb was in between 5-7.9 
g/dl while there were 13 patients (33.34 %) whose pre-transfusion 
Hb was in between 8-10.9 g/dl, 6 patients (15.38 %) had pre-
transfusion Hb less than 5 g/dl (fig. 6).  
The present study showed that 27 patients (69.23 %) came for blood 
transfusion once a month that is they were regular with their 
transfusions, 8 patients (20.15 %) came within 15 d, whereas 4 patients 
(10.26 %) were irregular with their blood transfusions (table 6). 
 
 
Fig. 1: Consanguinity 
 
 
Fig. 2: Age of diagnosis 
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In the present study it was found that among 39 patients; 11 (28.20%) 
had serum ferritin levels more than 1000 ng/ml, 3 patients (7.70%) 
showed less than 1000 ng/ml and for 25 patients (64.10%) reports 
regarding serum ferritin level were not available (fig. 7).  
From the collected data it was observed that 18 patients (46.53%) were 
started on chelation therapy based on their serum ferritin level to avoid 
iron overload in patients caused due to blood transfusions (table 7).  
The collected data showed that 21 patients (53.85 %) were prescribed 
with supportive therapy like calcium supplement and folic acid while 18 
patients (46.15 %) were not on any supportive therapy (table 8).  
Chronic blood transfusion can lead to many complications which 
require regular monitoring. In this study, it was observed that 
only 24 patients (61.54%) had their regular check-up was done 
(fig. 8).  
Among 24 patients who had been examined for complications, it was 
found that 12 patients (33.34%) had hepatosplenomegaly, followed 
by infection in 9 patients (25%), splenomegaly in 6 patients 
(16.66%), cardiac complications in 5 patients (13.88%), bone 
deformity in 3 patients (8.34%) and growth failure in 1 patient 
(2.78%). (fig. 9). 
  
Table 1: Demographic characteristics of beta thalassemia major patients and control group 
Characteristics Thalassemia patients Percentage (%) Control N= 28 Percentage (%) 
Gender 
Male 28 71.80 18 64.28 
Female 11 28.20 10 35.72 
Age (y) 
1-3 14 35.90 5 17.86 
4-6 9 23.08 14 50 
7-9 9 23.08 2 7.14 
10-12 2 5.13 2 7.14 
13-15 4 10.25 4 14.28 
16-18 1 2.56 1 3.58 
Education levels of children 
Preprimary 9 23.07 9 32.15 
Primary 10 25.65 13 46.43 
Secondary 6 15.38 6 21.42 
Left school 3 7.69 0 00.00 
Not attending school yet 11 28.21 0 00.00 
 
Table 2: Blood group distribution in thalassemia patients 
Blood group Number of patients Percentage (%) 
A+ 8 20.52 
B+ 14 35.90 
AB+ 4 10.25 
O+ 10 25.65 
B- 2 5.12 
AB- 1 2.56 
 
Table 3: Symptoms during diagnosis 
Symptoms Number of patients 
Pallor 28 
Fever 25 




Abdominal pain 3 
Vomiting 3 





Body ache 1 
Joint pain 1 
Others 2 
 
Table 4: Parent as carrier 
Parent as carrier Parents screened Percentage (%) 
Not screened 29 74.35 
2 Carrier 9 23.10 
1 Carrier 1 2.55 
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Fig. 3:-Hb at the age of diagnosis 
 
 
Fig. 4: Siblings details 
Quality of life of thalassemia pediatrics 
 
Fig. 5: Differences in quality of life between thalassemia 
pediatrics and control group 
 
 
Fig. 6: Mean pre-transfusion Hb level
 
Blood transfusion details of thalassemia pediatrics 






















1. 8 4 Once 540  1 Fever 1 
2. 8.4 6 Once 1476 1 Fever 1 
3. 8.4 6 Once 2346 1 No - 
4. 8.2 11 Twice 5680 2 Fever,  4 
5. 8.4 5 Once 746 1 No - 




7. 7.3 9 Twice 3420 1 Fever 4 
8. 4.3 4 Once 1460 1 Fever, lower 
back pain 
1 
9. 6.9 5 Once 1435 1 Fever 3 
10. 5.8 6  Once 5190 2 Headache, 
fever 
2 
11. 4.3 4 Once 2360 1 Fever, swelling 
at injection site 
1 
12. 6.2 6 Once 3194 1 Fever 1 
13. 5.1 6 Once 3780 1 Fever 1 
14. 4.6 8 Twice 3550 2 Fever and 
shivering 
2 
15. 9.13 5 Once 798 1 No - 
16. 8.2 8 Twice 4831 2 No - 
17. 4.54 5 Once 2544 1 No - 
18. 7.81 5 Once 1685 1 Fever 1 
19. 9.18 7 Once 586 1 Fever 2 
20. 7.9 7 Once 1668 1 No - 
21. 5.1 5 Once 3240 2 Vomiting 1 
22. 7.6 5 Once 2430 1 Fever 1 
23.  EXCLUDED      
24.* 5 2 Once 104 1 Fever 1 
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25. 8 8 Twice 2710 1 No - 
26. 7.81 6 Once 1729 1 Fever 1 
27. 7.91 3 Every 2 mo 3640 2 No - 
28. 7.1 11 Twice 1540 1 No - 
29. 9.01 6 Once 1030 1 No - 
30. 6.13 6 Once 900 1 No - 
31.  6.96 5 Once 1602 1 Fever, 
shivering 
2 
32. 8.51 8 Once 2065 1 No - 
33. 8.4 4 Once 498 1 Fever 1 
34. 5.87 4 Once 1066 2 No - 
35. 7.76 3 Once 569 1 No - 
36. 9.06 6 Once 949 1 No - 
37. 4.04 6 Twice 1562 1 Tachypnea, RD 2 
38.  EXCLUDED      
39.* 6.5 2 Once 120 1 Fever 1 
40.* 8.8 4 Once 428 1 No - 
41.* 3.8 2 Once 570 2 Fever 1 
* Newly diagnosed, RD-Respiratory distress, Abd. dist.-Abdominal distension 
 
Table 6: Frequency of blood transfusion 
Frequency of blood transfusion Number of patients Percentage (%) 
1 mo 27 69.23 
15 d 8 20.51 
Irregular 4 10.26 
 
Table 7: Chelation therapy in thalassemia patients 
Chelation therapy Started Not started 
Number of patients 18 21 
Percentage 46.15% 53.85% 
 
Supportive therapy in thalassemia pediatrics 
Table 8: Supportive therapy in thalassemia pediatrics 
Supportive therapy Number of patients Percentage (%) 
Yes 21 53.85 
No 18 46.15 
 
Management of iron overload due to blood transfusion 
 
Fig. 7: Serum ferritin level in thalassemia patients 
 
Complications associated with beta thalassemia major 
 
Fig. 8: Patients examined for complications 
 
Fig. 9: Complications associated with thalassemia 
 
DISCUSSION 
Thalassemia major is characterized by inadequate globin chain 
synthesis, leading to ineffective erythropoiesis, severe anemia and 
chronic disease in adulthood. 
The present study conducted for duration of 6 mo included 39 Beta-
thalassemia patients selected from Pediatric ward. Among which 
71.80 % were male and 28.20 % were female which is comparable 
to other studies which showed a higher occurrence among males 
than in females [8]. On the contrary, others study showed there was 
non-statistically significant difference observed between male and 
female thalassemia patients [9]. This difference in thalassemia 
patients (males more affected than females) is noteworthy and 
deserves further investigation considering thalassemia as a single 
gene disease transmitted by recessive mode of inheritance [10].  
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In this study frequency of patients with blood group, B+ve were 
higher (35.90 %) followed by patients with O+ve (25.65 %) while 
A+ve consisted of 20.52 % and AB+ve was 10.25 %. A similar study 
carried on beta-thalassemia patients showed a higher number of 
patients with blood group O+ve and lower number of patients with 
blood group B+ve. There was no significant difference found in 
blood group A+ve and AB+ve. This was in contrast with study 
conducted by Sharaf Kh H et al. which showed there was no effect of 
blood group on patients with Beta-thalassemia major [11]. 
The study reported that highest percentage of Beta-thalassemia 
major patients (50%) was in between the age grouped4-6 y. This 
result was comparable to the study conducted on the prevalence of 
beta-thalassemia by Qurat-ul-Ain et al. [10]. There is no correlation 
between age group and occurrence of Beta thalassemia major. Also, 
age group can vary from hospital to hospital.  
Consanguinity seems to play an essential role in causing Beta 
thalassemia major in the patients; in this study, it was observed that 
51.28% of patients were the product of the consanguineous 
marriage. A similar study conducted by Dorouddhi M et al. reported 
49.5% of patients were the product of consanguineous marriage [9]. 
There was one more study carried by Adaay et al. which showed 
71.4% of the patients were the product of consanguineous marriage 
[8]. The reason for same could be that the autosomal recessive trait 
will be more common in progeny of consanguineous parents since 
they have greater chance of inheriting identical copies of the mutant 
gene. Many studies have shown that consanguineous marriage plays 
a significant role in the expression of beta thalassemia in patients. 
In this study, it was observed that most of the patients (58.98%) 
were diagnosed with beta thalassemia major in the age range 
between 3-6 mo. The above results are consistent with study 
conducted by Kirti Grow et al. which reported that 51% of patients 
were diagnosed with beta thalassemia major before 8 mo of age 
[12]. A study conducted by Masyitah Sri Wahyuni et al. reported that 
more than half of the subjects were diagnosed with thalassemia at 
the age of less than 2 y, although they had been anemic before the 
age of 2 [13]. 
Symptoms of fever, pallor, cough, coryza, weakness were observed 
during diagnosis in our study. Similar clinical features of beta 
thalassemia major were reported in various studies conducted by P 
Sandhya Rani et al. and G Shanthi et al. respectively [3, 14]. Other 
symptoms which were not commonly seen were chills, irritability, 
abdominal pain, vomiting, decreased oral intake, diarrhea, edema, 
breathlessness, headache, body ache, joint pain were observed in 
this study. Symptoms like fatigue, facial bone deformities, 
protruding abdomen, yellowish discoloration of the skin and dark 
urine are among the other symptoms reported in a study [3]. 
Symptoms may depend upon the severity of the affected hemoglobin 
chain. 
It was found that of all thalassemic children’s parents, 23.10% had 
both parents as carriers, 1% had 1 parent as a carrier and in 74.35% 
of parents was not screened for beta thalassemia major. Similar 
results were found in a study conducted by Masyitah Sri Wahyuni et 
al. [13]. This could be because the marriage of two carrier parents 
results in 25% chance of producing thalassemic offspring, 50% 
chance of producing a carrier who can pass on the disease if he/she 
marries another carrier and a 25% chance of normal offspring. 
In this study incidence of beta thalassemia major among siblings was 
28.20%. A similar study was carried out by Tazeen Majeed et al. 
which reported the incidence of beta thalassemia trait among 58% 
of siblings [15]. A study conducted in Karachi reported 62.2% 
siblings as beta thalassemia carriers in immediate family members 
of patients [16]. 
The negative impact of the disease and its treatment can affect the 
quality of life in patients. In this study when the quality of life of 
thalassemic children was compared to control group it was found 
that the result was significantly lower. Age at onset of anemia, age at 
first transfusion, irregular iron chelation therapy and low pre-
transfusion hemoglobin levels were factors significantly affecting 
health-related quality of life. Various studies have reported that 
thalassemia pediatric had significantly lower health-related quality 
of life in all dimensions compared to their healthy counterparts [7, 
13]. Also, it was observed that among all four domains of quality of 
life, school function was a most affected domain. This may be 
because thalassemia children are frequently absent from school 
since they routinely go to the hospital for blood transfusion. Also 
one of the reasons for academic performance could be that 
thalassemia patients may face deprecatory remarks from their peers 
or teachers. A school environment that includes verbal abuse and 
less peer support for ill children may be a problem. Insufficient 
knowledge of teachers about the illness and the inability to spend 
adequate time with chronically ill children present barriers to the 
integration of the chronically ill child in a classroom situation. 
In the absence of adequate psychosocial intervention, chronically ill 
children may remain outside scope of formal education, something 
that in turn increases their isolation and misery which further 
affects the social life of the thalassemia patients. There is a need to 
develop a link between the patients, school officials, the family and 
the physician as they play an important role in helping children 
overcome this problem. 
As thalassemia is a type of anemia, improper oxygenation of cells 
can affect normal physical functions. This can lead to hindrance in 
patient’s day to day activities. The chronic nature of the disease, 
regular visit to hospitals for blood transfusions and decreased 
physical functions may have an influence on the emotions of the 
patients. This can make them more vulnerable to mental illnesses 
like anxiety and depression. 
In this study, we found that most of the patients had their mean pre-
transfusion Hb in the range of 5-7.9 gm/dl. The results of our study 
are comparable to the studies conducted by Masyitah Sri Wahyuni et 
al. and Mohaisen H Adaay et al. [13, 8]. These results of low Hb 
among patients can be explained by the limited health education of 
the parents about the disease, so that, blood transfusion was used 
only when the patient showed clinical symptoms caused by severe 
anemia or simply just to sustain life.  
Beta-thalassemia major is a transfusion dependent anemia requiring 
a lifelong blood transfusion for the afflicted patients to stay alive. In 
this study, it was observed that 69.23% came for blood transfusion 
once a month. The frequency of blood transfusion depends upon the 
age, severity of anemia, the rate of erythropoiesis, pre-transfusion 
hemoglobin level, blood type of the patient and availability of the 
blood.  
Commonly occurring adverse transfusion reactions in our study was 
fever, respiratory distress, swelling at the IV site, vomiting, 
headache, lower back pain, myalgia abdominal distension, and 
tachypnea. Fever during transfusion is thought to be caused by 
recipient antibodies reacting with white cell antigens or white cell 
fragments in the blood product or due to cytokines which 
accumulate in the blood product during storage. It is important to 
distinguish from fever due to the patient's underlying disease or 
infection (check pre-transfusion temperature). Fever may be the 
initial symptom in a more serious reaction such as bacterial 
contamination or hemolytic reaction. Myalgia, headache, and lower 
back pain can be associated with fever. 
Chronic blood transfusions can lead to iron overload in the body. It 
is necessary to monitor it regularly to avoid complication associated 
with iron overload. Serum ferritin is a good and practical method to 
monitor iron overload. Its level should be maintained below 1000 
ng/ml or soon it will get accumulated, causing various cardiac, 
hepatic and endocrine complications.9
Based upon the serum ferritin level (>1000 ng/ml), chelation 
therapy is initiated. In this study, 46.15% of patients were started on 
chelation therapy, and they were commonly prescribed with 
In this study it was found that 
28.20% of patients had serum ferritin above 1000 ng/ml while 
reports for 64.10% of patient’s reports were not available. This is 
because the reports of the thalassemic children were not maintained 
properly by the parents. Also, there were some patients in whom the 
serum ferritin test was not conducted; it could be due to low 
socioeconomic status of the patients. 
James et al. 
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deferasirox. The reason for prescribing this chelation therapy could 
be that it can be taken orally once daily and the patients are more 
compliant with the regimen as compared to other chelation therapy. 
Chelation therapy is initiated based on the number of transfusions a 
patient is receiving and whether the therapeutic goal is to decrease 
or maintain body iron levels [3]. 
The combination of transfusion and chelation therapy has 
dramatically extended the life expectancy of these patients, thus 
transforming thalassemia from a rapidly fatal disease of childhood 
to a chronic illness compatible with a prolonged life. On the other 
hand, frequent blood transfusions leading to iron overload and the 
chronic nature of the disease have contributed to a whole new 
spectrum of complications in adolescents and young adults suffering 
from thalassemia major. Complications which were observed in this 
study was hepatosplenomegaly (33.34%) and infections like HIV 
and sepsis (25%) followed by cardiac complication and bone 
deformity. A similar study was carried out by Kirti Grow et al. which 
reported growth failure as commonly occurring complication 
followed by cardiac and endocrine complications [12]. 
Hepatomegaly can be related to significant extramedullary 
hematopoiesis. Frequent blood transfusion can lead to iron 
overload, especially in the liver. The liver has a large capacity to 
produce proteins, which bind the iron and store it in the form of 
ferritin and hemosiderin. Therefore, it can produce severe iron 
overload [17]. Splenomegaly (enlarged spleen) is common in 
thalassemia major due to the high rate of hemolysis (red blood cell 
destruction). This takes place because the spleen sees the defective red 
cell of the thalassemic’s as deficient and the transfused red cells as 
invaders (much the same as with host vs. graft disease) and removes 
them from circulation. This hyperactivity of the spleen results in 
splenomegaly due to the amount of blood cells that are filtered out and 
also by a physical increase in size of the spleen so it can handle what it 
sees as a heavy load of blood cells that need to be filtered out. 
In this study, 53.85% were started on supportive therapy that is folic 
acid and calcium supplements. Folic acid is given because folic acid 
deficiency is a common complication in patients with beta 
thalassemia, mainly because of the extreme demand associated with 
the severe expansion of bone marrow, also poor absorption and 
intake can further contribute to its deficiency [18]. A calcium 
supplement is given to prevent osteoporosis, which is one of the 
complications of the disease [6]. This could be because of 
progressive marrow expansion, direct iron toxicity on osteoblasts 
due to iron overload, as well as liver disease. Furthermore, iron 
chelation therapy can be correlated with bone deformities. 
CONCLUSION 
Health-related quality of life of thalassemia children was found to be 
significantly lower than the control group and also adverse 
transfusion reactions and complications were observed in our study 
conducted at Bharati Hospital. By increasing the awareness and 
knowledge levels of the parents, it can be helpful to get better care 
locally and thus improve the quality of life in thalassemia children. 
Cognitive-Behavioral Family Therapy (CBFT) can be an effective 
psychological approach to children with beta thalassemia major, 
capable of increasing compliance to treatment, lessening the 
emotional burden of disease and improving the quality of life of 
children. It is important to identify and monitor transfusion-related 
adverse reactions so that we can improve the care given to the 
patients. Early detection of associated complications and adverse 
transfusion reactions in beta-thalassemia patients would be quite 
helpful to reduce the burden of disease through preventive measures. 
Creating awareness, genetic counseling, premarital and prenatal 
screening can be the best preventive measures that can be effective in 
the near future to avoid the occurrence of the disease in children. 
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